Unique to Canada, the patient support program (PSP) for a biologic is paid for by the manufacturer and a change in biologic medications means a change in PSP if the manufacturer is different. [...] biosimilar prescription? (n=15, displayed to respondents who often make an evaluation of drug benefits and cost, or who usually prescribe the lowest cost biologic drug in Q13) I would decide between the innovator and biosimilar depending on the individual I prescribe the biologic drug I believe is most 40%patient situation appropriate, regardless of cost to the public 63% system I would tend to pr. [...] • In Canada, the term "interchangeability" often refers to the ability for a patient to be changed from one drug to another equivalent drug, by a pharmacist, without the intervention of the prescriber who wrote the prescription. [...] In a situation where a payer (public or private) has the authority to province, how important would it be for you to have the authority to require a patient who is stable on their current biologic to switch to a designate a biologic medicine as "DISPENSE AS WRITTEN" or "DO NOT biosimilar, how important would it be for you to have the authority to SUBSTITUTE"? (n=41) designate a biologic medicine a. [...] How important is it to you to have the sole authority to decide, together with your patients, the most suitable biologic medicine for their disease? (n=41) Critical 27% Very important 63% Somewhat important 5% Slightly important 5% Not important 0% 10% 20% 30% 40% 50% 60% 70% % of Respondents 23 Biosimilar Substitution Q24.
- Pages
- 29
- Published in
- Canada
